Cellply, a Bologna-based deep tech company developing analytical tools for cell therapy and regenerative medicine, has secured €7.15 million in funding and opened a round extension to support its international growth plans. The round was led by Enea Tech and Biomedical Foundation, with participation from CDP Venture Capital and existing investors. The company is developing tools to characterize immunotherapies and cell-based therapies at single-cell resolution, with its flagship VivaCyte platform at the center of its commercial strategy.
With the fresh capital, Cellply will focus on two immediate priorities: accelerating the international expansion of VivaCyte across key global markets, and advancing next-generation automated functional testing solutions for advanced therapy medicinal product quality control. The latter aims to deliver greater precision in cell potency assessment while streamlining batch release processes, a critical bottleneck in the broader adoption of cell-based therapies.
VivaCyte combines patented microfluidic technology with AI-powered automated image analysis, comprehensive automation, and dedicated software to enable robust characterization of therapeutic modalities. Cellply said that as the industry moves toward increasingly complex and personalized medicines, standardized functional assays will become fundamental to enabling scalability, sustainability, and broader patient access globally.
In conjunction with the funding, Cellply welcomed Miro Venturi to its Board of Directors. Venturi is an industry veteran with decades of experience in global diagnostics, life sciences, and corporate leadership, having made significant contributions to precision medicine at scale. Cellply’s long-term ambition is to become the global leader in analytical tools for research and quality control within the cell therapy and regenerative medicine sectors.
KEY QUOTES:
“We are pleased to welcome Enea Tech and Biomedical Foundation as lead investor and to strengthen our shareholder base with the support of CDP Venture Capital and our existing investors. This investment provides the resources to accelerate our commercial expansion and advance innovative quality control solutions that can help unlock broader adoption of ATMPs worldwide.”
Alessia Zanelli, President and CEO, Cellply
“I am excited to join Cellply’s Board at such an important stage of the company’s journey. Cellply has built a highly differentiated technology platform addressing critical unmet needs in one of the most promising areas of healthcare innovation, supported by a top-notch team with strong capabilities in science and technology. I look forward to supporting the management team as they scale internationally, expand commercial adoption of VivaCyte, and advance new solutions for quality control in advanced therapies.”
Miro Venturi, Board Member, Cellply
